Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- LABB.MX
- Price
- 22.74
- Stock movement down
- -0.44 (-1.90%)
- Company name
- Genomma Lab Internacional S.A.B. de C.V
- Exchange
- (MX ,
- Currency
- MXN )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 21.56B
- Ent value
- 32.08B
- Price/Sales
- 1.23
- Price/Book
- 1.93
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- 24.16%
- Trailing P/E
- 13.45
- Forward P/E
- 9.67
- PEG
- -
- EPS growth
- 0.98%
- 1 year return
- 47.57%
- 3 year return
- 0.50%
- 5 year return
- 6.42%
- 10 year return
- 2.42%
Last updated: 2025-04-15
DIVIDENDS
LABB.MX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 13.45 |
| Price to OCF | 8.39 |
| Price to FCF | 8.74 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.23 |
| Price to Book | 1.93 |
| EV to Sales | 1.84 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 948.05M |
| EPS (TTM) | 1.69 |
| FCF per share (TTM) | 2.60 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 17.47B |
| Gross profit (TTM) | 11.10B |
| Operating income (TTM) | 3.66B |
| Net income (TTM) | 1.60B |
| EPS (TTM) | 1.69 |
| EPS (1y forward) | 2.35 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 63.56% |
| Operating margin (TTM) | 20.95% |
| Profit margin (TTM) | 9.18% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.83B |
| Net receivables | 4.76B |
| Total current assets | 12.19B |
| Goodwill | 0.00 |
| Intangible assets | 5.87B |
| Property, plant and equipment | 3.50B |
| Total assets | 23.51B |
| Accounts payable | 1.89B |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 6.72B |
| Total liabilities | 12.36B |
| Shareholder's equity | 11.15B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 2.57B |
| Capital expenditures (TTM) | 103.23M |
| Free cash flow (TTM) | 2.47B |
| Dividends paid (TTM) | 595.67M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 14.37% |
| Return on Assets | 6.82% |
| Return on Invested Capital | 9.76% |
| Cash Return on Invested Capital | 15.01% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 23.19 |
| Daily high | 23.22 |
| Daily low | 22.57 |
| Daily Volume | 2.41M |
| All-time high | 39.50 |
| 1y analyst estimate | 26.83 |
| Beta | 0.48 |
| EPS (TTM) | 1.69 |
| Dividend per share | - |
| Ex-div date | 13 Mar 2025 |
| Next earnings date | 22 Apr 2025 |
Downside potential
Loading...
Downside potential data
| LABB.MX | S&P500 | |
| Current price drop from All-time high | -42.43% | -12.89% |
| Highest price drop | -74.36% | -56.47% |
| Date of highest drop | 2 Feb 2009 | 9 Mar 2009 |
| Avg drop from high | -38.79% | -11.07% |
| Avg time to new high | 53 days | 12 days |
| Max time to new high | 2889 days | 1805 days |
COMPANY DETAILS
Marketcap
21.56B
Marketcap category
Large-cap
Description
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.
Employees
1633
Website
Investor relations
-
SEC filings
CEO
Country
Mexico
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its First Quarter 2025 Earnings Results on Wednesday, April 30, 2025, after t...
March 31, 2025
In recent weeks, global markets have been marked by volatility, with U.S. stocks experiencing losses amid inflation concerns and trade policy uncertainties. As investors navigate these challenging con...
March 21, 2025
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international ...
March 6, 2025
Genomma Lab Internacional SAB de CV (GNMLF) reports robust sales growth, significant profitability gains, and strategic plans for future expansion.
February 28, 2025
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the fourth quarter and full year ended December 31, 2024. All figures included here...
February 27, 2025
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its Fourth Quarter 2024 Earnings Results on Wednesday, February 26, 2025, aft...
February 10, 2025
As global markets navigate a mixed economic landscape marked by resilient labor markets and inflationary pressures, investors are closely monitoring the impact of these factors on stock valuations. Wi...
January 13, 2025
In a week marked by cautious commentary from the Federal Reserve and political uncertainty surrounding a potential government shutdown, global markets experienced notable volatility. Despite these cha...
December 27, 2024
In a week marked by mixed performances across major U.S. indices, with growth stocks significantly outpacing their value counterparts, investors are keenly observing the potential for undervalued oppo...
December 13, 2024
As global markets react to recent political shifts and economic policy changes, investors are keenly observing the implications of a "red sweep" in the U.S., which has driven major indices like the S&...
November 13, 2024
Next page